United States to India: Guaifenesin Import Trade Route

The United States to India Guaifenesin corridor is one of India's established pharmaceutical import routes from United States, with 10 shipments documented worth a combined $1.5K USD. The route is dominated by GRANULES PHARMACEUTICALS INC, which alone accounts for roughly 65% of all import value, reflecting the consolidated nature of United States's guaifenesin export sector.

Across 6 active United States suppliers, the average shipment value stands at $152 USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 79% of all shipments, consistent with guaifenesin's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 32 days port-to-port. The route has recorded an annual growth rate of 20.9%, placing it at rank #10 among India's top guaifenesin import origins globally.

On the Indian buyer side, key Indian importers include GRANULES INDIA LIMITED, RAPTIM RESEARCH PRIVATE LIMITED, DR REDDY S LABORATORIES LTD and 3 others. GRANULES INDIA LIMITED is the single largest Indian importer with 2 shipments valued at $981 USD.

India's guaifenesin imports from United States are driven primarily by a handful of large-scale United States manufacturers. GRANULES PHARMACEUTICALS INC with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 6 active exporters signals a competitive but concentrated market — Indian buyers benefit from United States supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — GRANULES PHARMACEUTICALS INC, GUARDIAN DRUG COMPANY, REED LANE INC — together account for 94% of total trade value on this route. The average shipment value of $152 USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as muciex dm (1200mg guaifenesin & 60mg dextromethorphan hbr erbi-layer tab) (7 packs x 42 tablets= 294 tablets) and reference product (r): mucinex d 1200mg guaifenesin&120mg pseudoephedrine hcl extended-release bi-layer tablets-(2x24=48reference product (r) mucinex d 1200mg guaifenesin&120mg pse, suggesting that Indian buyers tend to consolidate orders across related product lines from the same United States supplier.

On the buying side, GRANULES INDIA LIMITED is the largest importer with 2 shipments worth $981 USD — representing 65% of all guaifenesin imports from United States on this route. A total of 6 buyers are active on this corridor.